Fall is here, and America’s millions of CBD and hemp cannabinoid consumers still face an elusive expanse of rules and regulations that change as rapidly as the autumn leaves. 

• 90 new state bills would regulate hemp
• Cookies scores a University of Southern California deal
• And Cann’s 2mg Grapefruit Rosemary is delicious

Looking to make sense of the chaos? Leafly has you covered. Read on for your monthly news roundup of all things CBD, delta-8, THCA, and other hemp molecules.

Top CBD, delta-8 news of September

In a dramatic first for the hemp industry, the multinational brand Cookies has entered into a multi-year sponsorship deal with a university sports team. Beginning this season, Cookies will be an official sponsor for the University of Southern California Trojans football, as well as USC’s men and women’s basketball. According to a press release, “on-site tailgate experiences” will occur at select events; your good is as good as ours what that will look like. 

CBD and hemp legal news

In 2024 alone, US states have introduced 90 bills to regulate hemp. Yikes! The Libertarian-minded crew at the Reason Foundation recently dropped a proposal to streamline and standardize the US hemp industry. You can read it here.

California

Californians are “panic buying” thousands of dollars of CBD and other hemp products in advance of Governor Gavin Newsom (D)’s anticipated emergency ban on all hemp products containing trace amounts of THC in the Golden State. 

Missouri

Drama continues to unfold in Missouri, where Governor Mike Parson hopes to ban intoxicating hemp products. On September 18, the state health department rebuffed Parson’s plan. Hemp sales are back on, for the time being.

Texas

The Texas Supreme Court will consider whether to outlaw delta-8 sales in an upcoming case. According to the Texas Hemp Industries Association, the state’s hemp business is worth $8.1 billion, and delta-8 makes up a $6.8 billion piece of that pie.

US Federal

A US Circuit Court ruled on September 4 that the super-potent hemp-derived cannabinoid THC-O (aka THC-O acetate) qualifies as hemp, per language in the 2018 Farm Bill. The ruling puts the Court at odds with the DEA, who argue that THC-O does not meet the definition of hemp, and thus remains federally illegal. But since SupCo struck down the Chevron Doctrine this year, circuit courts no longer need to rely on a federal agency’s opinion to issue a ruling. We’ll see what happens next.

On October 15, the US Supreme Court will hear oral arguments in the case of a truck driver named Douglas Horn who failed a drug test after consuming a CBD product that allegedly did not contain any THC. Horn subsequently lost his job. He hopes to sue the manufacturers of the CBD product, Dixie X.. 

On September 4, the FDA sent a warning letter to a North Carolina-based skincare company called Root Bioscience Brands. The letter alleges that the company made medical claims about its CBD and other cannabinoid products that it does not have qualification to do, since CBD is not an approved drug. The company complied.

This one’s weird: Former Arkansas governor Mike Huckabee (R) is suing Meta (the parent company of Facebook). Huckabee alleges the company ran fake ads suggesting that he’s endorsing a CBD product. 

We love Cann’s 2 mg tonics!

We interrupt our news broadcast to offer a quick review on one of our favorite hemp-derived beverages Leafly HQ: Cann’s 2 THC mg Grapefruit Rosemary tonic. Packaged in a cute mini-can, this zippy beverage delivers a bouquet of subtle flavors and a clean, mellow buzz that helps it stand out among the competition. Cann’s products look classy, taste great and don’t launch you into a sugar rush (or subsequent nosedive).

CBD and hemp science news

Heads up, Leafly Nation. As we reported earlier this month, a new study shows that contrary to a widely-held belief, CBD can actually enhance cannabis’ psychoactive effects, not diminish them. 

Suppository success! A survey-based study found that Foria’s CBD suppositories reduced menstrual pain and discomfort for nearly four-fifths of all participants. 

Oregon State University has received $5 million to study the potential uses of industrial hemp.

CBD and hemp industry news

Big ups, CBD! According to a new report from InsightAce Analytic, the CBD ingredient market (aka products that include CBD as an ingredient) could more than double by 2031. The report estimates that CBD saw $2.42 billion in revenue in 2023, and that the figure could reach $6.77 billion by 2031.

The first CBD lozenge has landed in Canada, thanks to a collaboration between Aurora Cannabis and Vectura Fertin Pharma. Bon appetit.

Woodstock for hemp sippers is here: The inaugural Pacific Hemp Beverage Summit is going down on October 11, 2024 in Bend, Oregon. You can find more info about the event here.

And that’s it for Leafly’s monthly novel cannabinoids news roundup. As always, it’s the Wild West out there. We’ll see you next month to report on the latest.

While there is a need for more research, the data has good news.

The American Medical Association and the American College of Physicians along with the federal agencies Health and Human Services (HHS) and the Food and Drug Administration (FDA) have all spoke up about the need for additional research to unlock medical benefits of cannabis. The acknowledge it can help, but need more information, including more understand about dosage. Now, a study reveals more data about cancer and cannabis which only reenforces their call to action.

RELATED: Science Says Medical Marijuana Improves Quality Of Life

While cannabis is not a treatment for cancer, studies support marijuana-derived cannabinoids. TCH and CBD can help relieve symptoms and ease the side effects of cancer, including chemotherapy. More research can be done on treatment, but how do patients feel about using medical marijuana? The University of California San Diego and VA Health Care researchers partners for the one-year study. Team conducted a comprehensive survey of nearly 1,000 adult cancer patients at various stages of cancer treatment. What they discovered wasn’t a common sense surprise.

The lead researchers Corinne McDaniels-Davidson’s published in the Journal of the National Cancer Institute. They explored the decision-making process, perceived benefits, and risks of cannabis use to address symptoms in adults with cancer.

“There’s a vacuum in the world of cancer care. Many oncologists don’t talk to their patients about cannabis or refer them to a pain management specialist instead,” said McDaniels-Davidson, who is the associate director at the SDSU School of Public Health.

“Our data shows about a third of the patients surveyed used cannabis after their diagnosis, but only a few of those patients said they had told their oncologist,” said McDaniels-Davidson.

Cannabis has been used as medicine for thousands of years. The archeological site in the Oki Islands near Japan contained cannabis achenes from about 8000 BC, but it developed a bad name in the early 20th century. But the understanding it works is still strong. Survivors who perceived cannabis had any benefits were five times more likely to use it. Those who perceived there were any risks were nearly 60% less likely to have used it post-diagnosis.

RELATED: Biden Administration Puts A Knife Into The Cannabis Industry

According to the study, cancer survivors diagnosed with stage 3 or 4 were also more likely to use cannabis.  Among those who used cannabis, 19% said they believed the misconception that it could treat or cure cancer.  Cannabis can not cure cancer, a fact which needs to be made clear, but it increasing can help treat the disease. This study gives medical professional another tool to talk with patients.

Register Here

The cannabis industry is struggling. High taxes, market saturation and competition from outside sources have created a challenging business environment. Unfortunately, when a marijuana business fails, bankruptcy protection is off the table. As a result, the business is left with two options: to liquidate without court supervision, or state-court receivership.

We have spent a lot of time around cannabis receiverships recently. Our cannabis business and debtor/creditor lawyers have represented failing businesses, creditors, receivers, and a number of parties attempting to buy assets out of receivership sales.

Receivership is an equitable remedy, which means courts and receivers have significant leeway in the receivership process. Some states have receivership statutes, while others do not. Sometimes, clients are surprised to learn these facts, or to learn that many experienced debtor/creditor lawyers have never been in or around a receivership.

Please join cannabis insolvency lawyers Ethan Minkin (Arizona), Matthew Goldberg (Oregon, Washington, New York), and moderator Vince Sliwoski (Oregon) for a fascinating Q&A session on cannabis receiverships. Ethan and Matt have over 50 years of debtor/creditor lawyering experience between them, and Vince is a business lawyer who has counseled many clients through financial restructuring and business dissolution.

The conversation should be lively and educational, and the panel will take questions during the presentation– as well as any submitted in advance. So please send those along when you register!

We look forward to seeing you on September 24, at 12pm PST.

Register Here

NOTE: We have decided to also stream this Q&A live on LinkedIn and our Facebook pages.

Until then, for more on cannabis and receiverships, check out the following: